Following a thorough review, the Medicines and Healthcare products Regulatory Agency, or MHRA, has concluded that the available evidence does not establish a causal relationship between Glucagon-Like Peptide-1, or GLP-1, receptor agonists and suicidal behavior, suicidal ideation, self-injury and depression, the United Kingdom drug regulator announced. Novo Nordisk’s (NVO) Semaglutide, or Ozempic, and tirzepatide, or Mounjaro, which is marketed by Eli Lilly (LLY), are both injectable GLP-1 drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Health apps temporarily profiting from copycat weight-loss drugs, FT says
- Eli Lilly, EVA Pharma collaborate to expand access to baricitinib in Africa
- Trinity Biotech names Adrian Donohue as Chief Commercial Officer
- Statement from President Biden on anti-obesity medications pricing
- Viking Therapeutics selloff on Zepbound news an opportunity, says Truist